Ipratropium Bromide |
Presentation |
• 250mcg in 1ml nebule or polyamp | ||||||||||||
Pharmacology |
• Anticholinergic bronchodilator | ||||||||||||
Actions |
• Allows bronchodilatation by inhibiting cholinergic bronchomotor tone (i.e. blocks vagal refexes which mediate bronchoconstriction) | ||||||||||||
Metabolism |
• Excreted by the kidneys | ||||||||||||
Primary Emergency Indications |
• Severe respiratory distress associated with bronchospasm Adult Paed | ||||||||||||
Contraindications |
• Known hypersensitivity to Atropine or its derivatives | ||||||||||||
Precautions |
• Glaucoma • Avoid contact with eyes |
||||||||||||
Route of Administration |
• Nebulised in combination with Salbutamol | ||||||||||||
Side Effects |
• Headache • Nausea • Dry mouth • Skin Rash • Tachycardia (rare) • Palpitations (rare) • Acute angle closure glaucoma secondary to direct eye contact (rare) |
||||||||||||
Special Notes |
• There have been isolated reports of ocular complications (mydriasis, increased intraocular
pressure, acute angle glaucoma, eye pain) as a result of direct eye contact of Ipratropium
Bromide formulations • The nebuliser mask must therefore be ftted properly during inhalation and care taken to avoid Ipratropium Bromide solution entering the eyes • Ipratropium Bromide must be nebulised in conjunction with Salbutamol and is to be administered as a single dose only |
||||||||||||
Therapeutic Effect |
|